Published in Cancer Treat Rev on March 23, 2007
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Anticancer activity of metal complexes: involvement of redox processes. Antioxid Redox Signal (2011) 1.32
Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev (2013) 1.11
Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS One (2012) 1.08
Irinotecan and DNA-PKcs inhibitors synergize in killing of colon cancer cells. Invest New Drugs (2011) 0.91
[N,N'-Bis(salicylidene)-1,2-phenylenediamine]metal complexes with cell death promoting properties. J Biol Inorg Chem (2009) 0.85
Anticancer activity of methyl-substituted oxaliplatin analogs. Mol Pharmacol (2012) 0.84
Cisplatin inhibits protein splicing, suggesting inteins as therapeutic targets in mycobacteria. J Biol Chem (2010) 0.82
Acquired resistance to decitabine and cross-resistance to gemcitabine during the long-term treatment of human HCT116 colorectal cancer cells with decitabine. Oncol Lett (2015) 0.81
Antimetabolite Treatment for Pancreatic Cancer. Chemotherapy (Los Angel) (2014) 0.79
Treatment of stage IIIb/IV non-small cell lung cancer with Pemetrexed plus Oxaliplatin after failure of Erlotinib as second-line treatment. Med Oncol (2013) 0.75
Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study. BMC Cancer (2016) 0.75
Chromatin folding and DNA replication inhibition mediated by a highly antitumor-active tetrazolato-bridged dinuclear platinum(II) complex. Sci Rep (2016) 0.75
MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound. J Control Release (2017) 0.75
A pH responsive complexation-based drug delivery system for oxaliplatin. Chem Sci (2017) 0.75
Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model. Cancer Sci (2017) 0.75
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res (2010) 2.50
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol (2010) 2.31
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol (2012) 1.95
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol (2009) 1.70
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study. Lancet Oncol (2013) 1.59
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). Leuk Lymphoma (2014) 1.40
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol (2009) 1.40
Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev (2012) 1.32
A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev (2007) 1.27
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clin Cancer Res (2013) 1.22
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer (2012) 1.22
Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer (2011) 1.19
Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells Mol Dis (2002) 1.17
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling. Cancer Res (2009) 1.16
Microparticle-associated nucleic acids mediate trait dominance in cancer. FASEB J (2011) 1.13
A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Curr Cancer Drug Targets (2009) 1.11
Management of advanced gastric cancer. Expert Rev Gastroenterol Hepatol (2012) 1.09
The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. Asia Pac J Clin Oncol (2010) 1.05
Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J Vasc Interv Radiol (2011) 1.03
Antiangiogenic therapy for high-grade glioma. Cochrane Database Syst Rev (2014) 0.97
The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine. Lung Cancer (2011) 0.96
Current opinion on optimal treatment for colorectal cancer. Expert Rev Anticancer Ther (2013) 0.96
Health-related quality of life and inflammatory markers in malignant pleural mesothelioma. Support Care Cancer (2012) 0.95
The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer. Ann Surg (2017) 0.92
Patient-doctor communication: use of complementary and alternative medicine by adult patients with cancer. J Soc Integr Oncol (2010) 0.91
Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study. Asia Pac J Clin Oncol (2012) 0.89
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Rev Anticancer Ther (2014) 0.88
Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol (2002) 0.86
Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres. J Vasc Interv Radiol (2010) 0.85
A systematic review of the interobserver variability for histology in the differentiation between squamous and nonsquamous non-small cell lung cancer. J Thorac Oncol (2011) 0.83
Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis. Asia Pac J Clin Oncol (2014) 0.83
Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Crit Rev Oncol Hematol (2012) 0.82
Renal carcinoma associated with succinate dehydrogenase B mutation: a new and unique subtype of renal carcinoma. J Clin Oncol (2014) 0.81
A preliminary investigation of cell growth after irradiation using a modulated x-ray intensity pattern. Phys Med Biol (2006) 0.81
Predicting the clonogenic survival of A549 cells after modulated x-ray irradiation using the linear quadratic model. Phys Med Biol (2008) 0.81
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma. Lung Cancer (2013) 0.80
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clin Colorectal Cancer (2010) 0.80
Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. Medicine (Baltimore) (2015) 0.78
Streptavidin: a novel immunostimulant for the selection and delivery of autologous and syngeneic tumor vaccines. Cancer Immunol Res (2014) 0.78
Management of advanced neuroendocrine tumors with hepatic metastasis. J Clin Gastroenterol (2009) 0.77
ERCC1 expression and RAD51B activity correlate with cell cycle response to platinum drug treatment not DNA repair. Cancer Chemother Pharmacol (2008) 0.77
Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology (2011) 0.77
A 39 kDa fragment of endogenous ASK1 suggests specific cleavage not degradation by the proteasome. IUBMB Life (2008) 0.77
National Working Group Meeting on ALK diagnostics in lung cancer. Asia Pac J Clin Oncol (2014) 0.76
Similar chromosomal changes in cisplatin and oxaliplatin-resistant sublines of the H69 SCLC cell line are not associated with platinum resistance. Genes Chromosomes Cancer (2006) 0.76
Exhaled breath condensate for lung cancer protein analysis: a review of methods and biomarkers. J Breath Res (2016) 0.76
Platinum resistance needs the mythbusters. Toxicol Lett (2008) 0.75
The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Ther Adv Med Oncol (2013) 0.75
Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS One (2015) 0.75
Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev (2017) 0.75
A Longitudinal Investigation of Inflammatory Markers in Colorectal Cancer Patients Perioperatively Demonstrates Benefit in Serial Remeasurement. Ann Surg (2017) 0.75
EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer. Pathology (2014) 0.75
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev (2017) 0.75
Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors. Neuroendocrinology (2016) 0.75